Cardizem and Beta 2 microglobulin increased - a phase IV clinical study of FDA data

Summary:

Beta 2 microglobulin increased is reported as a side effect among people who take Cardizem (diltiazem hydrochloride), especially for people who are female, 50-59 old, also take Ms Contin, and have Hypercalcaemia.

The phase IV clinical study analyzes which people have Beta 2 microglobulin increased when taking Cardizem. It is created by eHealthMe based on reports of 27,075 people who have side effects when taking Cardizem from the FDA, and is updated regularly.

What is Cardizem?

Cardizem has active ingredients of diltiazem hydrochloride. It is often used in high blood pressure. eHealthMe is studying from 28,014 Cardizem users. Check the latest studies of Cardizem.

What is Beta 2 microglobulin increased?

Beta 2 microglobulin increased is found to be associated with 156 drugs and 190 conditions by eHealthMe. Check the latest studies of Beta 2 microglobulin increased.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 21, 2026

27,075 people reported to have side effects when taking Cardizem.
Among them, 11 people (0.04%) have Beta 2 microglobulin increased.

Could Cardizem cause Beta 2 microglobulin increased?

Among these 11 people:

What is the gender of people who have Beta 2 microglobulin increased when taking Cardizem? *

female: 100 %
male: 0.0 %

What is the age of people who have Beta 2 microglobulin increased when taking Cardizem? *

What are other drugs people take besides Cardizem? *

What are other side effects people have besides Beta 2 microglobulin increased? *

X-Ray Abnormal: 11 people, 100.00%
Hyperparathyroidism (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium): 11 people, 100.00%
Enterococcus Test Positive: 11 people, 100.00%
Extremity Necrosis (death of body tissue of arms and legs): 11 people, 100.00%
Facial Pain: 11 people, 100.00%
Hearing Loss: 11 people, 100.00%
Heart Disease: 11 people, 100.00%
Hip Fracture: 11 people, 100.00%
Hyperkalemia (damage to or disease of the kidney): 11 people, 100.00%
Hypokalemia (low potassium): 11 people, 100.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 11 people, 100.00%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 11 people, 100.00%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 11 people, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cardizem and have Beta 2 microglobulin increased?

- Check whether Beta 2 microglobulin increased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cardizem:

Cardizem (28,014 reports)

Browse all side effects of Cardizem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Beta 2 microglobulin increased:

Beta 2 microglobulin increased (156 drugs)

Browse all the conditions that are associated with Beta 2 microglobulin increased:

Beta 2 microglobulin increased (190 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on diltiazem hydrochloride (the active ingredients of Cardizem) and Cardizem (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.